18:28 , Jun 29, 2018 |  BC Week In Review  |  Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
21:19 , Jun 28, 2018 |  BC Extra  |  Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Celleron, Nuance Biotech deal

Celleron granted Nuance an exclusive option to develop and commercialize CXD101 and CXD201 in South Africa, Taiwan and China, including Macau and Hong Kong. CXD101 is a histone deacetylase (HDAC) inhibitor, and CDX201 is oral...
02:21 , Jan 8, 2016 |  BC Extra  |  Company News

Nuance gains territorial rights to Celleron candidates

Celleron Therapeutics Ltd. (Abingdon, U.K.) granted Nuance Biotech Inc. (Shanghai, China) an exclusive option for development and commercialization rights to oncology candidates CXD101 and CXD201 in Greater China and South Africa. CXD101 is an oral...
07:00 , Apr 1, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cutaneous T cell lymphoma (CTCL) RAD23 homolog B (RAD23B; HR23B); histone deacetylase (HDAC); proteasome In vitro and human studies suggest that HR23B could help predict...
07:00 , Jun 25, 2009 |  BC Innovations  |  Strategy

Science for export

Although every major university or institute would like to be located in a biotech hub and keep its discoveries close to home, only a few true hubs exist. For everyone else, the question is whether...
07:00 , Sep 25, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer E2F transcription factor 1 (E2F1); cyclin-dependent kinase 8 (CDK8); b-catenin Studies in flies and in human cell culture...
07:00 , Sep 25, 2008 |  BC Innovations  |  Targets & Mechanisms

CDK8 is Enough in Colorectal Cancer

Of the 11 known cyclin-dependent kinases, about half have long been the focus of cancer drug developers because they are involved in controlling cell-cycle progression, which goes into overdrive in cancer. However, none of the...
07:00 , Aug 4, 2008 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Celleron Therapeutics Ltd. Oxford, U.K. Technology: CancerNav biomarker identification technology Disease focus: Cancer Clinical status: Preclinical Founded: 2008 by David Kerr and Nick La Thangue University collaborators: Oxford University Corporate partners: 2 undisclosed Number of...
07:00 , Aug 4, 2008 |  BioCentury  |  Emerging Company Profile

Celleron: The sound of silence

Emerging Company Profile Many companies are trying to discover and validate biomarkers to help select the right patient populations for clinical trials. Celleron Therapeutics Ltd. is developing a cell-based functional screening platform that it believes...